Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Accumulated Expenses (2019 - 2025)

Biodesix (BDSX) has disclosed Other Accumulated Expenses for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 2.4% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2025, up 2.4%, and an annual FY2025 reading of $2.4 million, up 2.4% over the prior year.
  • Other Accumulated Expenses was $2.4 million for Q4 2025 at Biodesix, up from $637000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.6 million in Q1 2021 and bottomed at $37000.0 in Q1 2022.
  • Average Other Accumulated Expenses over 5 years is $1.7 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses tumbled 99.2% in 2022, then surged 710.58% in 2024.
  • Year by year, Other Accumulated Expenses stood at $2.8 million in 2021, then decreased by 16.31% to $2.3 million in 2022, then tumbled by 87.34% to $293000.0 in 2023, then soared by 710.58% to $2.4 million in 2024, then increased by 2.4% to $2.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for BDSX at $2.4 million in Q4 2025, $637000.0 in Q3 2025, and $2.4 million in Q4 2024.